Table 1.
Clinical practice guideline characteristics and development methods for recommendations.
| Guideline | Relevant content | Developers | Country/region | Target population | Type of evidence | Grading system |
|---|---|---|---|---|---|---|
| 2015; APA |
Use of antipsychotic medications when agitation or psychosis occurs in association with dementia | American Psychiatric Association | USA | Patients with dementia exhibiting agitation or psychosis | Randomized controlled trials, Systematic review, Expert opinion, Observational research, Patient values and preferences | YES |
| 2018; DELPHI |
Existing and emerging treatments for BPSD in Alzheimer's disease overall, as well as specifically for agitation and psychosis | Foreign expert group on psychiatry | International consensus panel | Patients with Alzheimer's disease exhibiting behavioral and psychological symptoms | Expert opinion, randomized controlled trials | NO |
| 2018; IPS |
Suggestions for the management of dementia | Indian Psychiatric Society | India | Patients with dementia | - | NO |
| 2018; CANADA |
When and how to safely taper and stop antipsychotics | Foreign expert group on psychiatry | Canada | Patients with behavioral and psychological symptoms of dementia and insomnia | Systematic reviews, expert consensus, randomized controlled trials | YES |
| 2018; NICE |
How dementia should be assessed and diagnosed | National Institute for Health and Clinical Excellence | United Kingdom | Patients with dementia | Systematic Reviews,Systematic review and Meta-analysis, Randomized controlled trials | YES |
| 2020; EAN |
Use of antipsychotics in dementia | European Academy of Neurology | Europe | Patients with dementia | Randomized controlled trials | YES |